iBio (IBIO) vs Pliant Therapeutics (PLRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
iBio (IBIO) has outperformed Pliant Therapeutics (PLRX) over the past year, gaining 5.7% versus a loss of 33.1%. Over five years, PLRX leads with a -94.5% price change compared with -99.8% for IBIO. Pliant Therapeutics is the larger company by market cap ($61.9 million vs $59.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBIO | PLRX |
|---|---|---|
| Share price | $0.92 | $1.00 |
| Market cap | $59.16M | $61.92M |
| 1-day change | -8.91% | +1.01% |
| YTD return | -52.33% | -18.85% |
| 1-year return | +5.75% | -33.11% |
| 5-year return | -99.80% | -94.50% |
| EPS (TTM) | $-0.32 | $-1.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.82 | $1.95 |
| 52-week low | $0.78 | $0.97 |
| Distance from 52-week high | -75.92% | -48.72% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +518.48% | +100.00% |
| Average volume | 735.37K | 477.96K |
| Shares outstanding | 64.31M | 61.92M |
| Employees | 23 | 49 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBIO has outperformed PLRX by 38.9 percentage points over the past year.
About iBio
IBIO stock →iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.
Healthcare · Biotechnology · 23 employees
About Pliant Therapeutics
PLRX stock →Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.
Healthcare · Biotechnology · 49 employees
IBIO vs PLRX FAQ
Which is bigger, iBio or Pliant Therapeutics?
Pliant Therapeutics (PLRX) is larger, with a market capitalization of $61.92M compared with $59.16M for iBio (IBIO).
Which stock has performed better over the past year, IBIO or PLRX?
IBIO returned +5.75% over the past 12 months, compared with -33.11% for PLRX (price return, excluding dividends). Past performance does not predict future results.
Are iBio and Pliant Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.